Background: Co-trimoxazole is a broad-spectrum antibiotic associated with hyperkalemia. Objective: To determine the incidence of hyperkalemia and its risk factors in patients receiving co-trimoxazole. Materials and Methods: A retrospective observational study involving all patients who received co-trimoxazole between 1 January 2012 and 1 January 2013 was conducted. Subjects were identified through a list generated from a computerized pharmacy system. The patients' demographic and clinical characteristics were retrieved from electronic medical records. Data were analyzed using univariate and multivariate logistic regression. Results: One hundred sixty-one patients fulfilled the eligibility criteria. Of these, 46 (28.6%) experienced hyperkalemia. Around 35 (76%) of the patients who experienced hyperkalemia received co-administered medications that might induce hyperkalemia. The coadministration of co-trimoxazole with other medications that may induce hyperkalemia was found to be associated with higher incidence of hyperkalemia when compared to cotrimoxazole administration alone [adjusted OR 3.2, 95% CI (1.4-7.3), p=0.005]. Additionally, age > 60 years was associated with an increased risk of hyperkalemia when compared to younger age group 18-39 years [adjusted OR 6.5, 95% CI (2.1-19.7); p=0.001]. Conclusion: Co-trimoxazole use is associated with high incidence of hyperkalemia, especially among older patients and those receiving it in combination with other medications that might contribute to hyperkalemia development such as calcineurin inhibitors and β-blockers.
Objective To evaluate the efficacy of pneumococcal vaccines concerning hospital or intensive care unit (ICU) admissions due to pneumonia after vaccination. Setting Inpatient and ICUs at Hamad General Hospital. Methods The retrospective study included adults who were vaccinated between June 2012 and June 2013. Patient records were reviewed for hospital or ICU admissions due to pneumonia 2 years before and after vaccination. Main outcomes measures The primary outcome was to compare the rates of hospital and ICU admissions for pneumonia 2 years before and after vaccination. The secondary outcome was to evaluate the efficacy of pneumococcal vaccines against different comorbidities. Key findings One hundred sixty-one patients were included with a dominant age group of 64-85 (52%) years old. Comorbidities reported were hypertension (HTN), diabetes mellitus (DM), chronic obstructive pulmonary disease (COPD) and asthma. The rate of hospital admission due to pneumonia was significantly reduced within 2 years after vaccination, 71-39% (P < 0.001). There was a trend towards reduced ICU admission (12.4-10.6%), but the results did not achieve statistical significance (P > 0.72). In diabetic, hypertensive and COPD/Asthma patients, there was a statistically significant reduction in hospitalization. Although there was a reduction in ICU admission for both commodities, the results did not achieve statistical significance. Conclusion Adults who received pneumococcal vaccines experienced reduced rates of hospital versus ICU admissions due to pneumonia infection.
Background: Co-trimoxazole is a broad-spectrum antibiotic associated with hyperkalemia, particularly in those with additional risk factors. Objectives: To determine the incidence of hyperkalemia and its risk factors in patients receiving cotrimoxazole. Methods: A retrospective observational study involving all patients who received co-trimoxazole between 1 January 2012 and 1 January 2013. Subjects were identified through a list generated from a computerized pharmacy system. The patients' demographic and clinical characteristics were retrieved from electronic medical records. Data were analyzed using univariate and multivariate logistic regression. Results: One hundred sixty-one patients fulfilled the eligibility criteria. Of these, 46 (28.6%) experienced hyperkalemia. Around 35 (76.1%) of the patients who experienced hyperkalemia received co-administered medications that might induce hyperkalemia. The co-administration of co-trimoxazole with other medications that may induce hyperkalemia was found to be associated with higher incidence of hyperkalemia when compared to co-trimoxazole administration alone [adjusted OR 3.2, 95% CI (1.4-7.3), p=0.005]. Additionally, age > 60 years was associated with an increased risk of hyperkalemia when compared to younger age group 18-39 years [adjusted OR 6.5, 95% CI (2.1-19.7); p=0.001]. Conclusion: Caution should be exercised in older patients and those receiving co-trimoxazole in combination with other medications, such as immunosuppressants and β-blockers that might contribute to hyperkalemia development.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.